Zimmer Biomet Debuts First-of-its-Kind Artificial Intelligence Capabilities for Omni™ Suite Intelligent Operating Room

Artificial Intelligence-Based Object Recognition Automates Manual Tasks and Data Collection to Optimize Operating Room Workflow Efficiency

WARSAW, Ind., May 10, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today introduced the availability of new artificial intelligence¹ (AI) capabilities within Omni™ Suite, an intelligent operating room (OR) designed to optimize surgical workflow and procedural efficiency by automating manual tasks and streamlining unnecessary technology and redundant hardware. The new AI feature uses cameras to automatically recognize and timestamp key OR workflow milestones, including patient entry and exit, door count, the start and stop of anesthesia, surgery and cleaning. Surgical teams are guided through a process to help optimize OR workflow based on real-time access to workflow metrics.

"Omni Suite is more than just another manual integration solution – it is a smart system designed to work with OR staff throughout the procedure," said Robert Kraal, Vice President and General Manager, Connected Health at Zimmer Biomet. "Now, with this new feature, surgical teams can utilize and rely on Omni Suite's AI capabilities to optimize OR workflow. By providing data points that have been historically captured manually, if at all, surgical teams can improve OR workflow and minimize manual activities, allowing more time for patient care."

Omni Suite's AI feature further expands the AI capabilities of ZBEdge™, a suite of integrated smart, digital and robotic technologies designed to deliver transformative data-powered clinical insights with the goal of improving patient outcomes. Last month, ZBEdge added powerful predictive analytics capabilities with WalkAI™, an AI model to predict post-operative gait (walking) speed recovery progress after hip or knee surgery.

"Omni Suite's latest feature further enhances the value and utility of the Omni Suite platform while adding AI capabilities to strengthen our ZBEdge Connected Intelligence Suite," said Ivan Tornos, Chief Operating Officer, Zimmer Biomet. "Omni Suite, along with the smart, digital and robotic solutions that make up ZBEdge, allow us to create value innovation that unlocks data-driven insights to enhance the surgical experience for surgeons, care teams and patients."

Omni Suite's AI feature is now available in the United States. For more information on Omni Suite's AI offerings, visit https://www.zimmerbiomet.com/en/products-and-solutions/specialties/intelligent-integration.html.  

About the Company
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

¹ The AI was developed to support the existing administrative tasks to enhance the efficiency of the OR workflow. The AI does not function to support any clinical decisions.

SOURCE Zimmer Biomet Holdings, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED